Surrogate reads like anecdotal is back in play.
Post# of 148087
" The FDA can grant accelerated approval based on a surrogate endpoint, which is something that is thought to predict clinical benefit. This allows for earlier access to drugs while confirmatory studies are still
___
If protocol includes Interim, with Dr. J, Syneos & Max, I would expect a fair Safety Board recommendation.
Of course we'd still need FDA to accept a SB recommendation of anything related to an Accelerated Approval.
Dr. J's FDA relationship comments sure ringing bells now.